Udenafil
Изглед
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Oralno |
| Identifikatori | |
| CAS broj | 268203-93-6 |
| ATC kod | None |
| PubChem | CID 6918523 |
| DrugBank | DB06267 |
| ChemSpider | 5293720 |
| Hemijski podaci | |
| Formula | C25H36N6O4S |
| Molarna masa | 516,656 |
| |
| |
Udenafil je organsko jedinjenje, koje sadrži 25 atoma ugljenika i ima molekulsku masu od 516,656 Da.[1][2][3][4]
Osobine
[уреди | уреди извор]| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 8 |
| Broj donora vodonika | 2 |
| Broj rotacionih veza | 11 |
| Particioni koeficijent[5] (ALogP) | 3,3 |
| Rastvorljivost[6] (logS, log(mol/L)) | -5,7 |
| Polarna površina[7] (PSA, Å2) | 126,3 |
Reference
[уреди | уреди извор]- ^ Ji HY, Shim HJ, Yoo M, Park ES, Lee HS: Transport of a new erectogenic udenafil in Caco-2 cells. Arch Pharm Res. Ji, H. Y.; Shim, H. J.; Yoo, M.; Park, E. S.; Lee, H. S. (септембар 2007). „Transport of a new erectogenic udenafil in Caco-2 cells”. Archives of Pharmacal Research. 30 (9): 1168—73. PMID 17958337. doi:10.1007/BF02980254.
- ^ Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. Ku, H. Y.; Ahn, H. J.; Seo, K. A.; Kim, H.; Oh, M.; Bae, S. K.; Shin, J. G.; Shon, J. H.; Liu, K. H. (јун 2008). „The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil”. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 36 (6): 986—90. PMID 18308836. doi:10.1124/dmd.107.020099.. Epub 2008 Feb 28.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889
. PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
- ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.